News

If approved by the FDA later this year, phentolamine ophthalmic solution 0.75% could be the only commercially available eye drop for the reversal of dilation. It is being developed for reversal of pharmacologically-induced mydriasis, presbyopia, and dim light vision disturbances under the 505(b)(2) pathway.

The findings from a National Institutes of Health-supported clinical trial may help guide the management of diabetic eye disease.

APAO returns to an in-person congress for the first time since the start of the COVID-19 pandemic.

Retina specialists help educate the public to take steps to protect their vision during AMD Awareness Month.

The goal of the National Eye Institute (NEI) is to shed light on rare diseases that affect every bodily system.

Rishi Singh, MD, presented data from the Phase 3 DERBY and OAKS clinical trials for geographic atrophy at the 2023 Angiogenesis, Exudation, and Degeneration conference.

Prof. Anat Loewenstein, MD, shares the latest research on home optical coherence tomography in relation to reactivations and responses in retina patients during her presentation at the virtual Angiogenesis 2023 conference.

Carl D. Regillo, MD, highlights the Talon Phase 3b results for brolucizumab vs aflibercept in a matched treat-and-extend superiority study for neovascular AMD at the virtual 2023 Angiogenesis conference.

In a presentation at the Angiogenesis, Exudation, and Degeneration 2023 conference, Justis Ehlers, MD, presented "Ellipsoid Zone Integrity in Dry AMD: An Imaging Biomarker for Progression Risk and Clinical Trial Endpoint.”

In a presentation at the 2023 Angiogenesis, Exudation, and Degeneration program, Usha Chakravarthy, PhD, FRCOphth, CBE, presented data from the trial of lampalizumab, which is peeling back some of the mystery shrouding geographic atrophy.

In a presentation at Bascom Palmer’s 2023 Angiogenesis, Exudation, and Degeneration conference in Miami, Pedro Lylyk, MD, said ophthalmic artery angioplasty could prove to be a treatment option for patients diagnosed with age-related macular degeneration.

A study conducted by Gemmy Cheung, MBBS, FRCOphth and colleagues shows geographic atrophy (GA) lesion phenotypes, associated features, and growth rates differ between Asians and non-Asians.

According to Regeneron, aflibercept injection is now approved to treat five retinal conditions caused by ocular angiogenesis.

According to investigators, the new discovery enhances our understanding of the previously unknown function of genomic regions outside the genes.

According to investigators pointed out that while good surgical results are obtained with small and medium-sized macular holes, it is important to determine the hole diameters at which the success rates of conventional surgery begin to decline.

The Phase 2 SPECTRA clinical trial will assess 4D-150 in patients with DME.

The vision care company is joining forces with the global nonprofit to fight avoidable blindness around the world.

According to the company, ONL1204 is a first-in-class small molecule Fas inhibitor with a mechanism of action designed to provide neuroprotection for retinal cells.

The Bascom Palmer program showcases neovascular, exudative, and degenerative eye diseases, and is designed for retina specialists, general ophthalmologists, and researchers.

According to a news release from Bausch + Lomb and biomedical laser company Modulight announced that the FDA has approved the ML6710i photodynamic laser for equivalent use with Visudyne.

According to a news release, the CDC is urging that clinicians and patients immediately discontinue the use of EzriCare Artificial Tears until the epidemiological investigation and laboratory analyses are complete.

According to the company, the approval allows Eyenuk’s EyeArt AI eye screening system, already approved for detection of diabetic retinopathy, to aid millions of additional patients at risk for vision loss.

Patients diagnosed with diabetic retinopathy may be particularly vulnerable to periods of low glucose, and keeping glucose levels stable should be an important part of glucose control.

Based on their findings, an international team of researchers is discouraging the application of atropine as a standard therapy for trabeculectomy surgery.

According to the company, it is planning an end-of-phase 2 meeting with the FDA to discuss the results.

The PRPH2 and Associated Retinal Diseases Workshop is designed to bring together leading experts from academia and industry, to discuss openly, and in detail, what is known about PRPH2 disease pathology, disease models, clinical characteristics, and therapeutic approaches.

A University of Houston researcher has been awarded a $1.6 million grant to help restore vision loss in patients with the rare disease that causes a progressive loss of vision, prompting retinitis pigmentosa.

A team of researchers have found that STOC tomography enables unprecedented views of eye structure.